Dr. Chase is a highly experienced biotech executive who has held senior leadership positions for companies in Canada, the United States and the United Kingdom including publicly traded companies listed on the TSX, Amex , Nasdaq and FTSE.

Dr. Chase joined the GeoVax Board in March 2015 where he serves on the Audit Committee, the Governance Committee and Chairs the Compensation Committee. 

Dr. Chase began his career at Bristol Meyers and then as a Senior Vice President at Glaxo Canada where he was responsible for manufacturing, R&D, clinical and regulatory functions, as well as overseeing the building of new Canadian headquarters and a state-of-the-art manufacturing facility. 

Subsequently he held positions as President of Quadra Logic Technology; President of Pasteur Merieux Connaught Canada (where he negotiated the largest ever Canadian Government investment in a biotech company for research on potential cancer vaccines); President of North American Vaccine in Columbia, Maryland (where he oversaw the sale to Baxter); Biochem Pharma/Shire Biologics; and President of Immunovaccine (where he took the company public). 

He has held Board of Director roles in various vaccine/oncology companies/organizations including Biojet, Biotech Canada, Tissue Regeneration Therapeutics, Acambis, and Conjuchem. He is the former Chairman of the Board for Medimabs, Glysantis and Medicago (sold to Mitsubishi Tanabe).

Dr. Chase graduated from Bishop’s University with an honors biochemistry degree; received his PhD from the University of British Columbia. He conducted postgraduate research at the McArdle Cancer Institute at the University of Wisconsin. He attended the Senior Executive Program at the London Business School in the United Kingdom and has advised young entrepreneurs in his role as Entrepreneur in Residence for the University Health Network at the University of Toronto.